WWiKY’s technology is unique. Through a better understanding of the hypoxic microenvironment (oxygen deprived environments), WWiKY is developing new diagnostic and therapeutic strategies that will exploit hypoxia to benefit and improve life quality of cancer patients. It will also help cancer researchers with technologies that enable molecular imaging, staging and therapy of hypoxic tumors.
WWiKY’s products include Hypoxycin-1™, a product currently approved by Health Canada for a Phase I/II clinical trial, Hypoxycin-M™, a cell hypoxia imaging agent, Hypoxycin-P™, a synthon forsynthesizing radiolabeled Hypoxycin-1 (PET or SEPECT), and apipeline of next generation ligand-based theranostics andnanotheranostics in collaboration with renowned scientists.